HBV前C区A1896基因突变的探讨及临床用药研究

Study on HBV Pre-c Region A1896 Gene Mutation and Clinical Drug

目的探讨慢性乙型肝炎A1896位点突变与HBV-DNA的关系及临床用药。方法选取慢性乙型肝炎患者230例,通过荧光定量PCR对乙肝病毒e抗原阴性的慢性乙型肝炎患者分别做病毒载量和A1896变异的检测,并对临床用药进行效果观察。结果慢性乙型肝炎患者乙肝病毒e抗原阴转后病毒复制尚未停止。结论乙肝病毒e抗原阴性A1896位点变异的患者抗病毒治疗时,恩替卡韦的效果显著。

Objective To investigate the relationship between A1896 site mutation of chronic hepatitis B and HBVDNA and its clinical use. Methods 230 patients with chronic hepatitis B were selected. The viral load and A1896 mutation of chronic hepatitis B patients with negative e antigen of hepatitis B virus were detected by fluorescence quantitative PCR, and the effect of clinical medication was observed. Results The virus replication of HBV e antigen in chronic hepatitis B patients was not stopped after negative transfer. Conclusion Entecavir is effective in antiviral therapy in patients with HBV e antigen negative A1896 site mutation.